Provider Reviews: Net Promoter Scores

October 25, 2016 | Posted by Christina Cordova in Company, Education, Helpful products |

One of the best advertisements for a product or service is a positive review from another customer.  Reviews and ratings are so compelling and commonplace, they help guide our choices in car repair, travel destinations, and sushi restaurants.  We think customer feedback is also incredibly useful when trying to find the right scientific service provider.  For this reason, we began collecting Net Promoter Scores (NPS) from our clients and sharing them on supplier storefronts.  

What is a Net Promoter Score?  In 2003 Bain & Company launched a new way to gauge customer loyalty and satisfaction by creating a feedback survey with a single question: “What is the likelihood that you would recommend Company X to a friend or colleague?”  Respondents answer this question on a scale of 0-10, with 10 being extremely likely and 0 being not at all likely.  Based on their response, customers who provide feedback are placed into one of three categories:


  • Promoters (9 or 10) are very satisfied clients who would urge others to buy from/work with the business
  • Passives (7 or 8) are satisfied, but unenthusiastic about their experience
  • Detractors (0-6) are unsatisfied customers who would share negative experiences about the company


The total Net Promoter Score is calculated by subtracting the number of detractors from promoters.  Identifying three key groups within a customer base allows for more targeted interaction with clients.  If someone marks a 6 or below, the company can follow up with that person and try to correct what went wrong.  

We took that idea and applied it to our feedback surveys for service providers.  Our rating system now includes detailed reviews contributed by other customers, as well as NPS information on each storefront.  We understand outsourcing decisions aren’t only based on price, but finding a service provider you can trust to conduct experiments vital to the success of your research.  In order to learn about our customers’ experience with a lab we ask the following questions:

  1. What is the likelihood that you would recommend (service provider) to a friend or colleague (0-10)
  2. How satisfied are you with the timeliness of the deliverables (0-10)
  3. How satisfied are you with the quality of the deliverables (0-10)

Integrating information like this on our platform is just one of the many ways Science Exchange provides industry insights that allow you to reduce risk when contracting with external service providers.  To read reviews and find the NPS information for a service provider, click on the Ratings tab on any storefront, as seen here.

Provider NPS image

Science Exchange empowers researchers to work with confidence and make informed outsourcing decisions across all industries. Search our Marketplace to choose from thousands of screened labs and feel free to add a review of your experience.  The unique feedback and NPS data you provide can help other teams find the right service provider for them.   

Find the right service provider for you and start your project today. 

Mass Spec: Shedding Light on Cancer Biomarkers with Century-Old Technology

October 5, 2016 | Posted by Christina Cordova in Research, Stories, Uncategorized |

Imagine telling the inventor of the radio that the technology he discovered was now found in almost every kitchen in America, and that you used it to make your popcorn last night. He’d probably be surprised, and maybe you are, too.  Sound far-fetched? Many aspects of modern life rely on technology that was first identified by 19th century physicists and then adapted to new applications. This not only includes microwave ovens from the example above, but state-of-the-art lab equipment which is poised to change the way researchers treat cancer. It might be hard to imagine cutting-edge discoveries in proteomics or precision medicine are the result of technology first conceived over a hundred years ago, but that’s what a new application called proteomic mass spectrometry imaging is doing for cancer diagnostic tests.

Many life scientists utilize research tools built on principles first explored and defined by physics, and mass spectrometry is a particularly impactful example. The technology we now use to measure mass-to-charge ratios of ions for the purpose of molecular analysis was first developed by J.J. Thomson on an instrument called a parabolic spectrograph in 1913. The spectrograph generated ions in gas discharge tubes, then passed the ions through parallel electric and magnetic fields. Subjecting the ions to these fields forced them to move in certain parabolic trajectories which would then be recorded on a photographic plate, as seen in the rather beautiful image below.

Discovery_of_neon_isotopesIt was Thomson’s research at the end of the 19th century that lead to the discovery of the electron, work that eventually won him the Nobel Prize in physics in 1906. To hear a 77 year-old Thomson talk about that research (and how very small electrons are at around the 2:50 mark), watch this video filmed in 1934.

Besides the name change (there aren’t any spectrographs in labs these days), mass spectrometry has come a long way technologically. Advances by subsequent researchers made the technology more precise and the resulting output more accurate. In 1920 the first modern mass spectrometer was developed by Arthur Dempster, of uranium isotope fame, and by the 1970s scientists had begun experimenting with joining liquid chromatography techniques to the process. In 1989 the first LC-MS instrument was launched, securing it as a ubiquitous technique now in its third decade of use. The staying power of this technology is due to its versatility; it is able to directly analyze any biological molecule receptive to ionization. Scientists can use LC-MS to better understand the molecular structure of everything from wastewater to skin cream. The data collected during analysis can inform evaluation of product effectiveness, environmental toxins, or the function of a protein. For this reason it provides valuable research applications in environmental analysis, consumer products, agriculture, and in this case, precision medicine.

Now a bona fide buzzword, the concept of precision medicine was catapulted into the social vernacular in 2015 when President Obama announced the Precision Medicine Initiative in his State of the Union Address. In practice, precision medicine isn’t entirely new; physicians and researchers have long understood the importance of individualized factors in treating or diagnosing patients. The concept of blood type matching and bone marrow donation registries are both examples of precision medicine we have accepted as standard treatments. Advances in biotechnology are ushering in a new emphasis on specialized medicine and carry with it the hope of more effective diagnostics and treatments for ailments like cardiovascular disease and cancer. Much of this promise rests on discoveries being made in the field of proteomics, particularly about the role of proteins in healthy cells versus diseased cells. The form, function, and interaction of these proteins can indicate the presence of disease, identify molecular therapeutic targets, and help define molecular disease taxonomies for future research. Finding a measurable indicator for any of these biological states is called a biomarker, making it the focus of many proteomics and cancer researchers.

It turns out, a very familiar technology is proving to be the best tool for unlocking the largely unknown world of proteins. LC-MS breaks down the complicated protein structures from their three dimensional form, and then into even smaller units called peptides. The quantitative analysis of these peptides makes it possible for scientists to identify protein expression profiles associated with certain cancers. Clinically viable biomarker panels could greatly increase early detection and definitive disease identification in patients, both of which are known to improve patient survival rate. This specificity in diagnosis allows patients and physicians to be better informed when making treatment decisions by understanding the disease on a molecular level. Biomarkers can improve standard differential diagnosis descriptions, which up to now have largely included physical symptoms that manifest at later stages of disease development, like metastasis. Some diseases like malignant melanoma present in very cryptic ways, making them difficult to diagnose, even for highly trained dermatopathologists. Inconclusive biopsy results or histological features that are also found in non-cancerous moles complicate diagnosis and can lead to costly mistakes in the course of treatment for such a common and potentially deadly disease. According to the American Cancer Society over 10,000 people will die this year from the disease, making it the most lethal of all skin cancers. A collaborative research project between Yale scientists and Protea Biosciences is seeking to change that with a new diagnostic technology. In April of this year they announced exclusive licensing for a method which uses unique protein expression profiles to discern the presence of cancer. The results of the first clinical study were presented in 2015, showing 99 percent accuracy in identifying malignant melanoma and benign melanocytic nevi.

Achievements like this highlight the benefit of partnerships between academia and industry, which are becoming more common in many sectors of biotechnology. If precision medicine is to become a reality, it will have to tackle complex disease models that have historically confounded individual pharmaceutical companies or research labs. Open innovation between researchers on both sides advances scientific discovery and expedites successful clinical implementation of potentially life-saving drugs. As scientists work on more complicated human health issues, they will need to find collaborators who are best suited to solve the research objective at hand, while accessing novel technologies best suited for the job.

Just as the concept of precision medicine has expanded with scientific discoveries in biotechnology, the technique of mass spectrometry has evolved to address new research questions with advances in bioinformatics and lab technology. Deciphering the human proteome is still a ways off, but innovative techniques and research partnerships will surely have a role to play in unlocking the power of proteomics for human health. As LC-MS capabilities continue to improve, new disease diagnostics and treatments will be added to the arsenal of options available to physicians. The next time you hear about an advancement in precision medicine (or pop a bag of popcorn), thank a physicist.

Looking for a cutting-edge collaborator like Protea to help with your research project? Visit our marketplace to find the right provider for your mass spec analysis, or any of the thousands of experiment types we offer.

Science Exchange is ISO 9001 Certified

September 16, 2016 | Posted by Christina Cordova in Company, Science Exchange News |

Science Exchange is proud to announce that we are now ISO 9001 certified. The Science Exchange team has always been invested in building a culture of continual improvement, and the work to get ISO certified underscores our commitment to delivering the highest quality services to our clients. The International Organization for Standardization (ISO) is the world’s largest facilitator of international standards and supervises national quality management system standards in over 150 countries.

What does an ISO Quality Management System (QMS) do?

A successful QMS system ensures that all aspects of business processes are efficient and responsive to organizational or client needs. Our rigorous QMS requires Science Exchange to adhere to certain standards and procedures which ensure fulfillment of our customer’s requirements. These guidelines provide us with a method of demonstrating our capability to provide services that ensure compliance with any and all applicable regulations across the globe, while continuously improving customer satisfaction.

What does ISO certification mean for our partners and customers?

Rigorous auditing conducted by an independent third party means doing business with Science Exchange secures a high level of quality assurance at every stage of your project. ISO compliance ensures we are working with consistent and effective methods, and that improving customer happiness is an ongoing goal for the entire team. These certification standards require continuous improvement and internal review; engaging clients for feedback and identifying areas of improvement will always be integral to our company philosophy.

ISO certification is just one initiative in our commitment to provide high-quality service to current and future partners. Visit Science Exchange and start your project today.

Kakapo 125 – First 40 kākāpō sequenced

August 4, 2016 | Posted by Team in Science Exchange News |

Kakapo Chick

Science Exchange is a collaborator in the Kakapo 125 Project. The objective of this project is to sequence the genomes of all known living kākāpō. We’re pleased to share an update on the project’s progress. NZGL has completed sequencing the first 40 individual kākāpō!


Sponsors of individual kākāpō genomes will shortly be receiving their custom DNA artwork produced by Nimble Diagnostics. Each DNA portrait is constructed from the genetic data of the individual kākāpō and is guaranteed to be unique. Genome sponsorship forms a key component of ongoing fundraising for the project as we strive to sequence every genome in an entire species.

sponsor a genome button

The data created as part of the Kakapo 125 Project will be made available to all researchers working on not-for-profit projects. To register your interest in the dataset generated to-date please send a request to The Department of Conservation (DOC).

We will soon be starting sequencing of the next 40 kākāpō genomes thanks to funding from a highly successful crowdfunding campaign on

Kakapo Running

Science Exchange is proud to be involved with this pioneering conservation initiative. Join Science Exchange today and work with us to accelerate your research.

The Importance of Replication Studies

July 28, 2016 | Posted by Team in Company, Reproducibility, Research, Science Exchange News, Uncategorized |

My TEDMED talk about scientific reproducibility was released today, so I wanted to take the opportunity to provide some additional thoughts about the importance of replication studies.

Every year, billions of dollars are spent funding biomedical research, resulting in more than one million new publications presenting promising new results. This research is the foundation upon which new therapies will be developed to enhance health, lengthen life, and reduce the burdens of illness and disability.

In order to build upon this foundational research, these results must be reproducible. Simply put, this means that when an experiment is repeated, similar results are observed. Over the last five years, multiple groups have raised concerns over the reproducibility of biomedical studies, with some estimates indicating only ~20% of published results may be reproducible (Scott et al. 2008, Gordon et al. 2007, Prinz et al. 2011, Steward et al. 2012, Begley and Ellis 2012). The National Institutes of Health (NIH), the largest public funder of biomedical research, has stated, “There remains a troubling frequency of published reports that claim a significant result, but fail to be reproducible. As a funding agency, the NIH is deeply concerned about this problem”.

Despite the growing concern over lack of reproducibility, funding for replication studies, the only way to determine reproducibility, is still absent. With no funding systematically allocated to such studies, scientists almost never conduct replication studies. It would be interesting to obtain the exact numbers, but it appears that last year the NIH allocated $0 to funding replication studies, out of a $30B+ budget. In the absence of replication studies, scientists end up wasting precious time and resources trying to build on a vast, unreliable body of knowledge.

It is easy to see why funders might shy away from funding replication studies. Funders want to demonstrate their “impact,” and it is tempting for them to solely focus on funding novel exploratory findings that can more easily be published in high profile journals. This is a mistake. Funders should instead focus on how to truly achieve their stated goals of enhancing health, lengthening life, and reducing the burdens of illness and disability. Although allocating a portion of funding towards replication studies would divert funds from new discoveries, it would enable scientists to efficiently determine which discoveries were robust and reproducible and which were not. This would allow more rapid advancements by allowing scientists to build upon the most promising findings and avoid wasting their time and funding pursuing non-robust results.

Some researchers find the idea of replicating previous studies unnecessary or even offensive. However, it is the responsibility of the scientific community, including funders, to work as quickly and cost effectively as possible to make progress. Introducing replication studies as part of the process provides an effective way to enable this.

If you would like to see funding specifically allocated for replication studies, please register your support. We will share this information with funders in the hope that it will encourage them to establish funding programs specifically for replication studies to improve the speed and efficiency of progress in biomedical research.

by Elizabeth Iorns, Ph.D.

CEO and Co-Founder

Science Exchange

About Science Exchange


Science Exchange is the world’s leading marketplace for outsourced research. The Science Exchange network of 3000+ scientific service providers has run the experiments for the major replication studies that have been conducted to date including the largest biomedical replication study undertaken (Reproducibility Project: Cancer Biology). Additional details are available here:



  4. Scott et al. Amyotroph Lateral Scler. 9, 4-15 (2008)
  5. Gordon et al. Lancet Neurol. 6, 1045–1053 (2007)
  6. Prinz et al. Nat Rev Drug Discov. 10, 712 (2011)
  7. Stuart et al. Experimental Neurology 233, 597–605 (2012)
  8. Begley and Ellis. Nature. 483, 531-3 (2012)



Science Exchange Acquires OnDeckBiotech to Expand Scientific Services Marketplace in Biotech Industry

June 7, 2016 | Posted by Team in Company, Science Exchange News, Uncategorized |

Science Exchange, the world’s leading marketplace for scientific research, announced today that it has acquired OnDeckBiotech, an international community and marketplace that connects biopharmaceutical companies with contract service providers. The acquisition brings together two of the major platforms for outsourced scientific services, and strengthens Science Exchange’s market-leading position by significantly increasing its global network of contract research organizations, core facilities, and other scientific service suppliers.

“Over $40B a year is spent on outsourced scientific research by the top 50 pharmaceutical companies alone, and much of this spend is highly fragmented across thousands of individual scientific service suppliers. Platforms for outsourced scientific services, like Science Exchange and OnDeckBiotech, solve the challenges associated with this fragmentation by providing scientists with efficient access to a diverse network of qualified suppliers under a single relationship,” said Dr. Elizabeth Iorns, Co-founder & CEO of Science Exchange. In praising the fit of the two companies, Iorns added, “OnDeckBiotech has developed a number of strategic relationships with industry groups and research foundations which complement the direct channels Science Exchange has developed with biopharmaceutical, government, and academic researchers.” OnDeckBiotech’s relationships, which include MassBio through the MassBio Gateway, the Biotechnology Innovation Organization (BIO) through BIO BizLink, and the Alzheimer’s Drug Discovery Foundation (ADDF) through ADDF ACCESS, will continue to be supported by Science Exchange as part of its strategy to become the ubiquitous platform for scientific outsourcing across all disease areas and stages of research and development.

As part of the acquisition, Science Exchange will take over OnDeckBiotech’s office in Cambridge, MA, giving Science Exchange a physical presence in two of the world’s largest and fastest growing biotech research clusters. “Science Exchange already works with 8 of the 10 largest pharmaceutical companies, many of which have invested heavily in these two clusters.  Now with offices in Palo Alto and Cambridge, in addition to Account Managers operating remotely in San Diego, New York, and other core markets, our team is uniquely positioned to help researchers inside these organizations access the world’s leading scientific service providers and most innovative scientific technologies,” said Iorns.

OnDeckBiotech’s Founder & CEO, Cliff Culver, will join Science Exchange as VP, Strategy and General Manager, Boston as part of the acquisition. “Cliff has been a visionary in the outsourced scientific services space, and we’re incredibly excited for him to join our team and continue our joint mission of enabling better, faster, and more efficient scientific collaboration,” said Dan Knox, Co-founder & COO of Science Exchange. Culver added, “We can’t wait to get started working with Science Exchange. The industry consistently reports that time and effort spent identifying and managing outsourced contracts hurts research productivity. Our companies have each demonstrated the value we can create by addressing these challenges, and our combined platforms and networks are uniquely positioned to continue to lead the market.”

Iorns concluded, “The total transactional volume of experiments conducted through the Science Exchange platform grew over 500% in 2015, and the OnDeckBiotech acquisition will further accelerate our already remarkable growth in 2016.”

About Science Exchange

Since its founding in 2011, Science Exchange has become the world’s leading marketplace for scientific research. Through Science Exchange, researchers can securely access a network of 1,000s of screened and verified contract research organizations (CROs), academic labs, and government facilities that are available to conduct scientific experiments. Science Exchange has been used by researchers from over 2,500 different companies and organizations, including many large pharmaceutical companies and government research facilities like the NIH, the FDA, and NASA. The company’s mission is to enable breakthrough scientific discoveries by providing researchers with easy access to the world’s best service providers. To date, the company has raised over $30 million from Maverick Capital Ventures, Union Square Ventures, Index Ventures, OATV, the YC Continuity Fund, and others.

Dan Knox, Co-Founder And COO Will Be Speaking At LabLaunch in Monrovia, CA

April 5, 2016 | Posted by Team in Company, Events |

Dan Knox, Co-Founder and COO, will be speaking at LabLaunch in Monrovia, CA, about how to use Science Exchange to order experiments from the world’s best labs. This event is part of the “Biotalk” seminar series which is a monthly educational networking event to support the current and potential biotech entrepreneurs of Los Angeles.
6:00pm-Networking and Refreshments
Thursday, April 14, 2016 from 6:00 PM to 7:30 PM (PDT)

LabLaunch-Monrovia – 605 Huntington Drive #103, Monrovia, CA 91016


Science Exchange Announces $25 Million in New Funding Led by Maverick Capital Ventures

March 23, 2016 | Posted by Team in Company, Science Exchange News, Uncategorized |

Science Exchange, the leading marketplace for scientific research, announced today that it has raised $25 million in new funding. The latest funding round was led by Maverick Capital Ventures and also included participation from Union Square Ventures, Index Ventures, YC Continuity Fund, Sam Altman, and others.

Since its founding in 2011, Science Exchange has become the world’s leading marketplace for scientific research services. The company provides secure access to a network of 1000s of screened and verified contract research organizations (CROs), academic labs, and government facilities that are available to conduct experiments on the behalf of scientists. The Science Exchange platform has been used by scientists from over 2,500 different companies and organizations. The company has experienced significant growth in the last 12 months, including seeing the total transactional volume of experiments conducted through the Science Exchange platform grow over 500% in 2015.

“Over $40B a year is spent on outsourced scientific research by the top 50 pharmaceutical companies alone. Much of this spend is highly fragmented across thousands of individual scientific service suppliers, and this fragmentation represents a challenge to both individual scientists and sourcing procurement departments,” said Dr. Elizabeth Iorns, Founder & CEO of Science Exchange. “The Science Exchange platform solves this challenge: we provide scientists with efficient access to a diverse network of qualified suppliers under a single relationship, and at the same time we provide sourcing departments with more information and control over their outsourcing spend.”

8 of the top 10 pharmaceutical companies now use Science Exchange, viewing it as a way to efficiently access innovative external resources. Science Exchange also helps tackle one of the most significant challenges facing the highly-trained researchers at these companies: time and resources spent identifying and managing outsourcing contracts. James Lillie, VP In Vitro Biology at Genzyme (a Sanofi company), was recently quoted as saying, “We now look at the Science Exchange as the best way of finding new outsourcing opportunities with collaborators and CROs. We’re shifting more of our efforts for new outsourcing contracts there.”

As part of the Series B, Maverick Capital Ventures Managing Partner David Singer (former Founder/CEO of Affymetrix, GeneSoft Pharmaceuticals, and Corcept Therapeutics) will join the company’s board. “We spent a lot of time evaluating the growing market for outsourced scientific services. We concluded first, that there is an expanding market need for a marketplace to aggregate the thousands of suppliers, and second, that Science Exchange is poised to become the ubiquitous platform for scientific outsourcing,” said Singer.

Andy Weissman, Partner at Union Square Ventures, who has been on the company’s board since 2013, agrees. “With over 500% growth in marketplace transaction volume in 2015 and some companies already spending over $1M each month on the platform, Science Exchange is the clear market leader,” said Weissman.

Science Exchange is headquartered in Palo Alto, CA, and has clients, including many large pharmaceutical companies, around the globe. The company has now raised over $30 million and plans to use the new funding to expand its team in all areas including product, engineering, sales, marketing, and customer success. The full list of investors in the latest round is Maverick Capital Ventures, Union Square Ventures, Index Ventures, OATV, YC Continuity Fund, Windham Venture Partners, Collaborative Fund, Fenwick & West, Jose Suarez (CEO of TEDMED), Sam Altman, Steve Case, Kal Vepuri, Jenny Haeg, Alexander Levy, Paul Buchheit, and Silicon Valley Bank.




A Voyage Through the PacBio Genome Galaxy

March 16, 2016 | Posted by Team in Science Exchange News |

We are pleased to support the Genome Galaxy Initiative from PacBio. SMRT Sequencing Technology manufacturer PacBio recently unveiled the Genome Galaxy Initiative. The Genome Galaxy Initiative, based on the Experiment platform, supports expedited, open-access genomic projects. It’s a central location for SMRT Sequencing-based projects seeking crowdfunding, and fosters a community of scientists and patrons interested in asking research questions that can only be answered with long-read sequencing. As high-quality genome assemblies from the PacBio RS II and the Sequel System have become even more affordable and accessible, partnering with Experiment is a great fit. Through this program, even more scientists will have access to the most comprehensive view of genomes, transcriptomes, and epigenomes from SMRT Sequencing.

The Genome Galaxy Initiative

One of the initiatives flagship participants is the Kakapo 125 Project. An effort to sequence the genomes of every individual in the entire kākāpō species. This project was made possible thanks to the high quality reference genome generated by Dr. Jason Howard at Duke’s Jarvis Lab using SMRT Sequencing technology.

Kakapo Jasira

Other projects in the Genome Galaxy include efforts to find bacteria within ticks to stop diseases, as well as an investigation into the incredible nitrogen capturing properties of the fern Azolla. In addition to fostering a growing community of SMRT Sequencing related projects PacBio is also offering a grant program exploring the “most interesting genome” as voted for by the public. 2016 applications for this grant are now closed with a winner to be announced in April.

Science Exchange is also assisting in the Genome Galaxy Initiative with a number of its projects including the Kakapo 125 being managed on its platform. As well as hosting many of the projects Science Exchange is also the easiest and most comprehensive place to find SMRT Sequencing service providers.


The Genome Galaxy Initiative is another great example of the industry coming together to support open access science and to help out with funding at the grassroots level. Science Exchange is excited to be affiliated with this initiative and looks forward to seeing many new and exciting stars being discovered there.

Visit Science Exchange and See Our New Look!

February 25, 2016 | Posted by Team in Company, Helpful products, New Feature, Science Exchange News |

For many people who use Science Exchange, a visit to the homepage is the first step in accomplishing their research objective. For requesters, service providers, or anyone using our network, the web experience is a crucial part of each project. With that in mind, we are excited to announce that we have refreshed the site, including an entirely new homepage. We have kept the same handy tools you will need to start and manage your research project, but improved the look and feel of some key pages. Search our marketplace for thousands of Science Exchange Verified Providers and request a quote in minutes. If your project is more specialized, you can partner with one of our staff scientists to find a perfect fit for your research needs with our concierge service. Every project is covered by the Science Exchange Guarantee, ensuring that your research can begin quickly, safely, and with complete IP protection. Science Exchange is an ideal partner for researchers who want to focus on science instead of sourcing, and progress instead of payment terms. We work with the world’s best suppliers to make scientific discovery faster, easier, and more reproducible. Providing scientists with a single relationship which manages compliance, contracts, and payments allows them to focus on the research goal at hand while collaborating with our cutting-edge providers. We think breakthrough discoveries should happen at the rate of science, not protracted negotiation. Take a look at our ever-growing network to explore how we can help with your next project.Screen Shot 2016-02-25 at 4.34.47 PM

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By